Ivosidenib and Azacitidine combination shows significant clinical benefit in newly diagnosed IDH1-mutated AML
16463
post-template-default,single,single-post,postid-16463,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Ivosidenib and Azacitidine combination shows significant clinical benefit in newly diagnosed IDH1-mutated AML

Home > Blogs  > Ivosidenib and Azacitidine combination shows significant clinical benefit in newly diagnosed IDH1-mutated AML

30 Apr Ivosidenib and Azacitidine combination shows significant clinical benefit in newly diagnosed IDH1-mutated AML

Posted at 10:44h in Blogs by

n patients with newly diagnosed IDH1-mutated AML who were ineligible for intensive induction therapy, Ivosidenib/Azacitidine combination showed significantly longer EFS compared to Azacitidine at a median follow-up of 12.4 months. The median OS was 24.0 months with Ivosidenib/Azacitidine and 7.9 months with Azacitidine. Febrile neutropenia and infections were less frequent with Ivosidenib/Azacitidine than Azacitidine.
(Ref: Montesinos P et al. N Engl J Med. April 21,2022)

#oncologyresearch #drugdevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6926072382784704512

No Comments

Sorry, the comment form is closed at this time.